Medicare quietly gains power to approve lung cancer tests without full review

What it does

This bill expands Medicare's coverage of lung cancer screening tests by allowing the HHS Secretary to approve additional FDA-cleared screening tests beyond those currently covered, without requiring a formal determination process. The Secretary has discretion to decide which tests qualify, how often they can be used, and how much Medicare will pay, with input from medical experts and the Agency for Healthcare Research and Quality. The change takes effect immediately upon enactment.

Why we flagged it

The bill amends Section 1834 of the Social Security Act to authorize Medicare to cover additional FDA-cleared lung cancer screening tests beyond those currently covered under national coverage determination 210.14. It delegates discretionary authority to the Secretary of Health and Human Services to determine which tests qualify, frequency, and payment limits.

What the text implies

• Grants HHS Secretary broad discretionary authority to approve lung cancer screening tests without requiring a formal Section 1861 determination, potentially accelerating coverage decisions for new diagnostic technologies and reducing procedural oversight.
• The phrase 'as determined by Sec.' appears three times without explicit criteria, creating regulatory flexibility that could favor certain test manufacturers or diagnostic modalities depending on how the Secretary interprets 'appropriate individuals' and 'appropriate' frequency/payment limits.

The full analysis lists 4 implications of this text.

Who stands to gain

diagnostic imaging companies; in vitro diagnostic (IVD) manufacturers; pharmaceutical companies with oncology portfolios